Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases

Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases

The association between hyperuricemia and cardiovascular diseases has been studied for many years. Research has shown a link between high uric acid levels and increased risk of including coronary artery disease hypertension and other cardiovascular conditions. Urate-lowering therapy, particularly wi...

Full description

Bibliographic Details
Main Authors:	Franklin Sosa, Mohammed Shaban, Jose Lopez, Gustavo J. Duarte, Swati Jain, Asma Khizar, Timothy Vittorio, Rishabh Mishra, Miguel Rodriguez Guerra
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-03-01
Series:	Clinical Medicine Insights: Cardiology
Online Access:	https://doi.org/10.1177/11795468241239542

Similar Items

Advances in Urate Excretion and Urate Transporters in Hyperuricemia
by: XIN Jiadong, ZHOU Jiabao, WU Zhiyuan, ZHANG Xuming, GAO Jiandong
Published: (2023-05-01)

Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound
by: Davide Viggiano, et al.
Published: (2018-04-01)

Comparative efcacy and safety of urate-lowering therapy for the treatment of hyperuricemia
Published: (2018-05-01)

Bergenin as a Novel Urate-Lowering Therapeutic Strategy for Hyperuricemia
by: Mo Chen, et al.
Published: (2020-07-01)

Chronic kidney disease: the role of hyperuricemia and the possibility of urate-lowering therapy
by: M. S. Eliseev
Published: (2018-04-01)

Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy
by: M S Eliseev, et al.
Published: (2019-05-01)

Efficacy and safety of urate-lowering agents in asymptomatic hyperuricemia: systematic review and network meta-analysis of randomized controlled trials
by: Tunlanut Sapankaew, et al.
Published: (2022-06-01)

Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
by: Hee Jung Jeon, et al.
Published: (2019-01-01)

Seasonal variations for newly prescribed urate-lowering drugs for asymptomatic hyperuricemia and gout in Japan
by: Masafumi Kurajoh, et al.
Published: (2024-01-01)

Hyperuricemia, urate-lowering therapy, and kidney outcomes: a systematic review and meta-analysis
by: Gaurav Sharma, et al.
Published: (2021-05-01)

Role of genetic polymorphisms in clopidogrel response variability: a systematic review
by: José López, et al.
Published: (2023-11-01)

Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
by: Aleš Kvasnička, et al.
Published: (2023-12-01)

Two cases of acute urate nephropathy in women with asymptomatic hyperuricemia
by: L. N. Yeliseyeva, et al.
Published: (2021-03-01)

Protective effects of Cyclocarya paliurus on hyperuricemia and urate-induced inflammation
by: Li-Hua Zhu, et al.
Published: (2022-07-01)

Hyperuricemia and Progression of Chronic Kidney Disease: A Review from Physiology and Pathogenesis to the Role of Urate-Lowering Therapy
by: Tao Han Lee, et al.
Published: (2021-09-01)

Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis
by: Lin Zhang, et al.
Published: (2022-01-01)

Urate-lowering therapy for CKD patients with asymptomatic hyperuricemia without proteinuria elucidated by attribute-based research in the FEATHER Study
by: Hiroshi Kataoka, et al.
Published: (2022-03-01)

Research progress on related factors of pathogenicity of urate crystals in patients with asymptomatic hyperuricemia
by: Zhong Yang, Wang Lijuan, Wang Yuanli, Li Yasong
Published: (2022-02-01)

Gout - asymptomatic hyperuricemia with/without asymptomatic monosodium urate crystal deposition: To be treated or not?
by: Radak-Perović Marija, et al.
Published: (2019-01-01)

Eggshell Membrane Ameliorates Hyperuricemia by Increasing Urate Excretion in Potassium Oxonate-Injected Rats
by: Yoon-Young Sung, et al.
Published: (2021-09-01)

Urate-lowering therapy for gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database
by: Masataka Honda, et al.
Published: (2021-12-01)

Uric acid, gout and cardiovascular diseases: prospects for the use of urat-lowering medications
by: M. S. Eliseev, et al.
Published: (2019-08-01)

Engineered Escherichia coli Nissle 1917 with urate oxidase and an oxygen-recycling system for hyperuricemia treatment
by: Rui Zhao, et al.
Published: (2022-12-01)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
by: Philip K. Tan, et al.
Published: (2017-04-01)

Diuretic resistance and the role of albumin in congestive heart failure
by: Carol Fernandez Hazim, et al.
Published: (2023-12-01)

Urate-lowering therapy for heart failure
by: O. V. Zhelyabina, et al.
Published: (2019-09-01)

Molecular Elucidation of a Urate Oxidase from <i>Deinococcus radiodurans</i> for Hyperuricemia and Gout Therapy
by: Yi-Chih Chiu, et al.
Published: (2021-05-01)

Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
by: Kateryna Pierzynowska, et al.
Published: (2020-11-01)

Konjac glucomannan improves hyperuricemia through regulating xanthine oxidase, adenosine deaminase and urate transporters in rats
by: Yuan Zhang, et al.
Published: (2018-09-01)

The impact of adoption of a new urate-lowering agent on trends in utilization and cost in practice.
by: Yueh-Lung Peng, et al.
Published: (2019-01-01)

Chicory (Cichorium intybus L.) inhibits renal reabsorption by regulating expression of urate transporters in fructose-induced hyperuricemia
by: Yu Wang, et al.
Published: (2019-01-01)

Hyperuricemia exacerbates abdominal aortic aneurysm formation through the URAT1/ERK/MMP-9 signaling pathway
by: Jen-Chun Wang, et al.
Published: (2023-01-01)

Cordycepin, a Characteristic Bioactive Constituent in Cordyceps militaris, Ameliorates Hyperuricemia through URAT1 in Hyperuricemic Mice
by: Tianqiao Yong, et al.
Published: (2018-01-01)

Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout
by: Rebekah Wrigley, et al.
Published: (2020-03-01)

Pu-erh ripened tea resists to hyperuricemia through xanthine oxidase and renal urate transporters in hyperuricemic mice
by: Ran Zhao, et al.
Published: (2017-02-01)

Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency
by: Mian Wu, et al.
Published: (2021-03-01)

The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion
by: Kazi Mirajul Hoque, et al.
Published: (2020-06-01)

Gout, hyperuricemia and cardiovascular risk
by: A E Iljina, et al.
Published: (2009-02-01)

Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2
by: Yu Toyoda, et al.
Published: (2019-10-01)

Alpha-mangostin counteracts hyperuricemia and renal dysfunction by inhibiting URAT1 renal transporter in insulin resistance rat model
by: Vivian Soetikno, et al.
Published: (2022-07-01)